Erlosiban

• CAT Number: I006703
• CAS Number: 1477482-19-1
• Molecular Formula: C20H22N2O3
• Molecular Weight: 338.41
• Purity: ≥95%
• Synonyms: OBE-001; OBE001; OBE001; Erlosiban;[(2S,4Z)-2-(hydroxymethyl)-4-(methoxyimino)pyrrolidin-1-yl](2/’-methyl[1,1/’-biphenyl]-4-yl)methanone
• Target: oxytocin receptor antagonist
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: [(2S,4Z)-2-(hydroxymethyl)-4-methoxyiminopyrrolidin-1-yl]-[4-(2-methylphenyl)phenyl]methanone
• InChI: InChI=1S/C20H22N2O3/c1-14-5-3-4-6-19(14)15-7-9-16(10-8-15)20(24)22-12-17(21-25-2)11-18(22)13-23/h3-10,18,23H,11-13H2,1-2H3/b21-17-/t18-/m0/s1
• InChIKey: OLUJSZLBWZWGJT-HGBKYHTQSA-N
• SMILES: CC1=CC=CC=C1C2=CC=C(C=C2)C(=O)N3CC(=NOC)CC3CO

Erlosiban(CAT: I006703) is an oxytocin receptor antagonist that has been studied for its potential to prevent preterm labor and improve fertility outcomes in assisted reproductive technologies (ART). By blocking oxytocin receptors, Erlosiban inhibits uterine contractions, reducing the risk of premature labor and supporting embryo implantation in IVF procedures. It is valuable in research focused on reproductive health, particularly for conditions related to uterine contractility and labor management. Erlosiban holds promise as a therapeutic tool in improving pregnancy outcomes in women undergoing fertility treatments or at risk of preterm birth.